CN101686919A - 瓜氨酸用于治疗与蛋白质羰基化增加相关的病理学状态的用途 - Google Patents

瓜氨酸用于治疗与蛋白质羰基化增加相关的病理学状态的用途 Download PDF

Info

Publication number
CN101686919A
CN101686919A CN200880009440A CN200880009440A CN101686919A CN 101686919 A CN101686919 A CN 101686919A CN 200880009440 A CN200880009440 A CN 200880009440A CN 200880009440 A CN200880009440 A CN 200880009440A CN 101686919 A CN101686919 A CN 101686919A
Authority
CN
China
Prior art keywords
citrulline
treatment
composition
nutrition
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880009440A
Other languages
English (en)
Chinese (zh)
Inventor
C·莫纳德
S·沃兰德
Y·伯瑞
L·希诺伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auvergne University
CT HOSPITALIER UNIVERSITAIRE D
Assistance Publique - Hôpitaux de Paris
Institut National de la Recherche Agronomique
Université Paris Descartes
Original Assignee
Auvergne University
CT HOSPITALIER UNIVERSITAIRE D
Assistance Publique - Hôpitaux de Paris
Institut National de la Recherche Agronomique
Université Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auvergne University, CT HOSPITALIER UNIVERSITAIRE D, Assistance Publique - Hôpitaux de Paris, Institut National de la Recherche Agronomique, Université Paris Descartes filed Critical Auvergne University
Publication of CN101686919A publication Critical patent/CN101686919A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Birds (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
CN200880009440A 2007-03-22 2008-03-20 瓜氨酸用于治疗与蛋白质羰基化增加相关的病理学状态的用途 Pending CN101686919A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0702090 2007-03-22
FR0702090A FR2913885B1 (fr) 2007-03-22 2007-03-22 Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines
PCT/FR2008/000379 WO2008135661A2 (fr) 2007-03-22 2008-03-20 Utilisation de la citrulline pour pour le traitement de pathologies liees a une augmentation de la carbonylation des protéines

Publications (1)

Publication Number Publication Date
CN101686919A true CN101686919A (zh) 2010-03-31

Family

ID=38561836

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880009440A Pending CN101686919A (zh) 2007-03-22 2008-03-20 瓜氨酸用于治疗与蛋白质羰基化增加相关的病理学状态的用途

Country Status (8)

Country Link
US (1) US20100093863A1 (cg-RX-API-DMAC7.html)
EP (1) EP2136777A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010522146A (cg-RX-API-DMAC7.html)
CN (1) CN101686919A (cg-RX-API-DMAC7.html)
CA (1) CA2689608A1 (cg-RX-API-DMAC7.html)
FR (1) FR2913885B1 (cg-RX-API-DMAC7.html)
IL (1) IL200830A0 (cg-RX-API-DMAC7.html)
WO (1) WO2008135661A2 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102600260A (zh) * 2010-12-24 2012-07-25 漆又毛 一种氨基酸和提取物组合物防治老年性痴呆的药物用途
CN105147684A (zh) * 2015-09-30 2015-12-16 暨南大学 胡椒碱在制备防治败血症药物中的应用
CN106137782A (zh) * 2015-04-22 2016-11-23 捷通国际有限公司 包含青藤碱的局部组合物及用于抑制蛋白羰基化的方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2685987B1 (en) * 2011-03-18 2019-04-24 Nestec S.A. Compositions and methods useful for ameliorating age related maladies
JP2014512372A (ja) * 2011-04-18 2014-05-22 ネステク ソシエテ アノニム α−HICA及びエイコサペンタエン酸を含有する栄養組成物
WO2014125376A2 (en) * 2013-02-15 2014-08-21 Mediterranean Institute For Life Sciences Protein damage in aging and age-related diseases
JP7220838B2 (ja) * 2015-09-29 2023-02-13 学校法人北里研究所 経口組成物
KR102531118B1 (ko) * 2023-01-05 2023-05-11 주식회사 마이크로엑스 패혈증의 예방, 개선 또는 치료용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
FR2691359B1 (fr) * 1992-05-20 1995-06-23 Krempf Michel Nouvelle application therapeutique du malate de 1-citrulline.
DE4341000A1 (de) * 1993-12-02 1995-06-08 Beiersdorf Ag Verwendung von L-Arginin, L-Ornithin oder L-Citrullin und topischen Zubereitungen mit diesen Stoffen
FR2766712B1 (fr) * 1997-08-01 1999-10-22 Aguettant Lab Composition de preference solution antioxydante et medicaments en faisant application
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
DE19929993C2 (de) * 1999-06-30 2001-07-05 Sueddeutsche Kalkstickstoff Kreatin-alpha-ketoglutarate, Verfahren zu ihrer Herstellung und ihre Verwendung
NL1014380C2 (nl) * 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
JP3843298B2 (ja) * 2001-02-05 2006-11-08 国立大学法人 奈良先端科学技術大学院大学 シトルリンを含有する活性酸素消去剤
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
FR2853210B1 (fr) * 2003-04-02 2006-12-15 Neolait Sas Composition activateur de la digestion
US20060247207A1 (en) * 2003-07-01 2006-11-02 Pierzynowski Stefan G Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition
FR2857262B1 (fr) * 2003-07-08 2007-10-05 Biocodex Lab Utilisation de la citrulline dans le cadre de l'insuffisance intestinale
JP3878612B2 (ja) * 2004-03-01 2007-02-07 ピアス株式会社 活性酸素抑制用の組成物と、その組成物を配合する皮膚外用剤及び化粧料
FR2869539B1 (fr) * 2004-04-29 2008-08-08 Univ Paris Descartes Compositions pharmaceutiques pour la prevention et le traitement de l'atherosclerose
JP4887499B2 (ja) * 2004-04-30 2012-02-29 国立大学法人 奈良先端科学技術大学院大学 野生種スイカ抽出物を含有する活性酸素消去剤ならびに保湿剤
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease
JP4255432B2 (ja) * 2004-10-28 2009-04-15 株式会社ファンケル 異常蛋白質除去用組成物
WO2006131054A1 (en) * 2005-06-04 2006-12-14 Zichun Li Chinese pharmaceutical ophthalmological formulations in forms of solutions, ointments and pills for antiaging recovery
JP5188181B2 (ja) * 2005-08-25 2013-04-24 協和発酵バイオ株式会社 血中アルコール濃度上昇抑制用組成物
CA2648126C (en) * 2006-04-04 2012-12-18 Nestec S.A. Treatments using citrulline
FR2907011B1 (fr) * 2006-10-17 2010-05-14 Univ Paris Descartes Utilisation de la citrulline pour le traitement des etats de denutrition

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102600260A (zh) * 2010-12-24 2012-07-25 漆又毛 一种氨基酸和提取物组合物防治老年性痴呆的药物用途
CN106137782A (zh) * 2015-04-22 2016-11-23 捷通国际有限公司 包含青藤碱的局部组合物及用于抑制蛋白羰基化的方法
CN105147684A (zh) * 2015-09-30 2015-12-16 暨南大学 胡椒碱在制备防治败血症药物中的应用

Also Published As

Publication number Publication date
FR2913885A1 (fr) 2008-09-26
CA2689608A1 (fr) 2008-11-13
WO2008135661A2 (fr) 2008-11-13
IL200830A0 (en) 2010-05-17
WO2008135661A3 (fr) 2009-01-15
US20100093863A1 (en) 2010-04-15
FR2913885B1 (fr) 2012-07-20
JP2010522146A (ja) 2010-07-01
EP2136777A2 (fr) 2009-12-30

Similar Documents

Publication Publication Date Title
Grimble Adverse gastrointestinal effects of arginine and related amino acids
JP4850986B2 (ja) カルノシンあるいはその誘導体および分枝アミノ酸を含む抗酸化活性を有する医薬組成物および/または栄養組成物
JP6023428B2 (ja) ラミニン332産生促進組成物
WO2010002242A1 (en) Nutritional composition for improving muscle function and daily activity
JP5826032B2 (ja) コラーゲン産生促進組成物
US20100093863A1 (en) Use of citrulline for preventing an increase in protein carbonylation and for treating diseases resulting therefrom
JP3287842B2 (ja) 免疫刺激剤としてのアルギニンの用途
TW201039858A (en) Composition for alleviating ultraviolet radiation-induced damage
CN101605538A (zh) 瓜氨酸用于治疗营养缺乏状况的用途
JP5795960B2 (ja) 紫外線障害軽減組成物
CN114072147A (zh) 使用葫芦巴碱和高蛋白质来预防或治疗骨骼肌病症或障碍的组合物和方法
WO2019104851A4 (zh) 一种β-羟基丁酰-氨基酸化合物及制备方法和应用
CN111491656A (zh) 采用高蛋白质诱发自噬的组合物和方法
US20190008813A1 (en) Lithium salts of n-substituted glycine compounds and uses thereof
WO2002100393A1 (fr) Compositions destinees a ameliorer les troubles de manque d'attention/d'hyperactivite
JP2014031323A (ja) セラミド産生促進用組成物
JP2022538584A (ja) 骨格筋における状態又は障害を予防又は治療するための、トリゴネリン及びミネラルを使用する組成物及び方法
KR20120080165A (ko) 주름 형성 경감 경구 조성물
Farges et al. Oral administration of a glutamine-enriched diet before or after endotoxin challenge in aged rats has limited effects
JP2941787B2 (ja) 多価不飽和脂肪酸を含有する医薬組成物および健康食品
RU2223670C1 (ru) Биологически активная добавка к пище
US20240408044A1 (en) Composition
JP5317456B2 (ja) 内因性オピオイドペプチドの血中分泌促進用組成物
WO2013015288A1 (ja) リパーゼ活性阻害剤
JP2024020094A (ja) 低用量グルタチオンの肌の明度向上剤としての使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20100331